Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial
Details : WCK 5222, a combination of cefepime and zidebactam, is in a Phase 3 trial for complicated urinary tract infections globally.
Brand Name : WCK 5222
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
LOOKING FOR A SUPPLIER?
Reset All
